2001, volume 17, issue 4


Mechanizm działania leków neuroleptycznych z perspektywy psychofarmakologii

Wojciech Kostowski
Farmakoterapia w Psychiatrii i Neurologii, 2001, 4, 295-312

Interaction of neuroleptics with dopamine receptors is generally accepted to be important for their antipsychotic action. So called "atypical" neuroleptics are mostly associated with a lower propensity for extrapiramidal side effects. It has been postulated that a low affinity and fast dissociation from the dopamine D2 receptor are important characteristics of atypicals. The neuroleptic drugs have been reported to act as inverse agonists at D2 receptors. It is suggested that this property may be important for the antipsychotic effects of drugs.


Psychozy schizoafektywne – kryteria rozpoznawania i zasady farmakoterapii zaburzeń

Małgorzata Rzewuska
Farmakoterapia w Psychiatrii i Neurologii, 2001, 4, 322-360

Diagnostic criteria for schizoaffective psychoses were compared in various classifications. Research results concerning the prevalence, the course, and prognostic signs in this group of psychoses were presented. Strategies of schizoaffective psychoses treatment proposed by various expert groups were discussed. The author's own project of pharmacotherapy of these disorders was outlined as well.


Inhibitory acetylocholinesterazy w leczeniu choroby Alzheimera

Iwona Kłoszewska
Farmakoterapia w Psychiatrii i Neurologii, 2001, 4, 361-369

Choliensterase inhibitors are a new class of psychotropic drugs used in the symptomatic treatment of Alzheimer’s disease (AD). Cholinergic deficit is considered to be responsible for the impairment of cognitive functions found in dementia. Inhibition of the acetylcholine inactivating enzyme results in the increased activity of the cholinergic system. There are four drugs registered for the treatment of AD, three of them are available in Poland. The results of clinical studies concerning tacrine, donepezil, rivastigmine and galantamine are presented in this paper. Therapeutic effects of each drug in improving cognitive functions, the level of activities of daily living and behavioural disorders in mild and moderate stages of AD are significant, although modest.